AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23168228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQ group): PPI + amoxicillin for 5 days followed by PPI + clarithromycin + metronidazole for 5 days
Number of subjects: 323
Study 23168228 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (AM group): PPI + amoxicillin + metronidazole for 7 days
Number of subjects: 323
Study 23168228 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (AC group): PPI + amoxicillin + clarithromycin for 7 days
Number of subjects: 323
Study 23168228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQ group)
Number of subjects: 323
Study 23168228 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (AM group)
Number of subjects: 323
Study 23168228 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (AC group)
Number of subjects: 323
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for alliance
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for non-positive learning statements received from counselor
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for participation variables
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for self-disclosures about the past
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for group cohesion
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for degree of participation of each group member
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for positive feedback
Number of subjects: 0
Study 21409739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped group drug counseling sessions rated for negative feedback
Number of subjects: 0
Study 18242535 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation of all pulmonary veins (PVs)
Number of subjects: 105
Study 18242535 — intervention group
Group type: COMPARATOR
Intervention: Isolation of arrhythmogenic pulmonary veins
Number of subjects: 105
Study 16813477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position pelvic-floor muscle exercises
Number of subjects: 44
Study 16813477 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine and upright position pelvic-floor muscle exercises
Number of subjects: 44
Study 16813477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined (collapsed data)
Number of subjects: 44
Study 14519796 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 186
Study 14519796 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 186
Study 14519796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DASH and Control diets with reduced sodium intake
Number of subjects: 186
Study 14519796 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with reduced sodium
Number of subjects: 186
Study 10741082 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (Total Intravenous Anesthesia) using a mixture of propofol (45 ml of 1%) and alfentanil (2,500 micrograms)
Number of subjects: 32
Study 10741082 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthetic technique (isoflurane/N2O, sufentanil)
Number of subjects: 32
Study 8767028 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1414227 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of phenytoin (PT)
Number of subjects: 29
Study 1414227 — intervention group
Group type: COMPARATOR
Intervention: Control group (PT not changed)
Number of subjects: 29
Study 2865615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate patches
Number of subjects: 0
Study 2865615 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 28986682 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP fibrin glue pleurodesis
Number of subjects: 52
Study 28986682 — intervention group
Group type: COMPARATOR
Intervention: Surgical thoracic duct ligation
Number of subjects: 52
Study 27325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing instruction time
Number of subjects: 0
Study 27325778 — intervention group
Group type: EXPERIMENTAL
Intervention: General increase in instruction time
Number of subjects: 0
Study 24639419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (HOP)
Number of subjects: 65
Study 24639419 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional peanuts (CVP)
Number of subjects: 65
Study 24639419 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 65
Study 22218066 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide-containing cellulose dressing
Number of subjects: 30
Study 22218066 — intervention group
Group type: COMPARATOR
Intervention: Polyhexanide swabs
Number of subjects: 30
Study 20185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic, deep abdominal and pelvic floor muscle retraining (n = 35)
Number of subjects: 70
Study 20185357 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitored pelvic floor muscle exercises (Control group, n = 35)
Number of subjects: 70
Study 20185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic, deep abdominal and pelvic floor muscle retraining
Number of subjects: 70
Study 20185357 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitored pelvic floor muscle exercises
Number of subjects: 70
Study 17765364 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) diet (SAFA 8%, MUFA 23%)
Number of subjects: 11
Study 17765364 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat (SAFA) diet (SAFA 17%, MUFA 15%)
Number of subjects: 11
Study 15685460 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting of the central third of the patellar tendon
Number of subjects: 17
Study 12433647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of puerarin injection
Number of subjects: 72
Study 12433647 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of anisodamine
Number of subjects: 72
Study 10234289 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines
Number of subjects: 0
Study 10234289 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations (EBR)
Number of subjects: 0
Study 10234289 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guidelines
Number of subjects: 0
Study 10234289 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical practice based on scientific evidence
Number of subjects: 0
Study 8607174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily (n=77)
Number of subjects: 150
Study 8607174 — intervention group
Group type: COMPARATOR
Intervention: High dose intravenous steroids (IVS) 5 mg/kg for 5 days (n=73)
Number of subjects: 150
Study 8607174 — intervention group
Group type: COMPARATOR
Intervention: High dose intravenous steroids (IVS)
Number of subjects: 150
Study 8607174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150
Study 1945993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.25 mg/kg)
Number of subjects: 14
Study 1945993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6784809 — intervention group
Group type: COMPARATOR
Intervention: Enema (Control group: 149 women)
Number of subjects: 274
Study 6784809 — intervention group
Group type: EXPERIMENTAL
Intervention: No enema (Experimental group: 125 women)
Number of subjects: 274
Study 6784809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Enema and No enema)
Number of subjects: 274
Study 30607677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical FDX104 4% foam applied twice daily for 5 weeks
Number of subjects: 0
Study 30607677 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam (placebo) applied twice daily for 5 weeks
Number of subjects: 0
Study 30607677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical FDX104 4% foam
Number of subjects: 0
Study 28376235 — intervention group
Group type: EXPERIMENTAL
Intervention: CEAwatch protocol
Number of subjects: 238
Study 28376235 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 238
Study 28376235 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection by CEA measurement
Number of subjects: 238
Study 28376235 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection by CT
Number of subjects: 238
Study 25964400 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated PPD screening at 6 and 12 months postpartum
Number of subjects: 1432
Study 23375786 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPUS (14 osteotomies)
Number of subjects: 27
Study 23375786 — intervention group
Group type: COMPARATOR
Intervention: Control (13 osteotomies)
Number of subjects: 27
Study 21175277 — intervention group
Group type: EXPERIMENTAL
Intervention: Software recommendations for insulin dosage adjustments
Number of subjects: 26
Study 21175277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy titrated every 1-4 weeks
Number of subjects: 26
Study 19837741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led intensive care follow‐up programmes
Number of subjects: 286
Study 19837741 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 286
Study 18300511 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule YD
Number of subjects: 63
Study 18300511 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine methods)
Number of subjects: 63
Study 15281518 — intervention group
Group type: EXPERIMENTAL
Intervention: isobaric clonidine (150 microg)
Number of subjects: 30
Study 15281518 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric clonidine (150 microg)
Number of subjects: 30
Study 11497396 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim (2 microg/kg daily, s.c.)
Number of subjects: 139
Study 11497396 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 139
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus rotavirus vaccine (RV‐TV)
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 1 of RV‐TV
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 2 of RV‐TV
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 3 of RV‐TV
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque purification and serotyping after Dose 1
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque purification and serotyping after Dose 2
Number of subjects: 248
Study 9613651 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque purification and serotyping after Dose 3
Number of subjects: 248
Study 8021329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose transdermal nicotine (21 or 22 mg/day for 6 weeks)
Number of subjects: 208
Study 8021329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered-dose transdermal nicotine (21 or 22 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks)
Number of subjects: 208
Study 8021329 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg TID for 7 days, then 10 mg TID for 21 days)
Number of subjects: 208
Study 2563951 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated mesalazine (Mesasal) 1.5 g daily
Number of subjects: 220
Study 2563951 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine 3.0 g daily
Number of subjects: 220
Study 31492505 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily) plus a P2Y12 inhibitor for 12 months
Number of subjects: 1506
Study 31492505 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) in combination with a P2Y12 inhibitor and aspirin (100 mg once daily, for 1-12 months)
Number of subjects: 1506
Study 29733106 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 82
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TEP with lightweight PPM
Number of subjects: 48
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral repair
Number of subjects: 48
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger mesh
Number of subjects: 48
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller mesh and unilateral repairs
Number of subjects: 48
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TEP
Number of subjects: 48
Study 26541729 — intervention group
Group type: EXPERIMENTAL
Intervention: General health
Number of subjects: 48
Study 24787143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/d
Number of subjects: 602
Study 24787143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/d
Number of subjects: 602
Study 24787143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 22318383 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% tretinoin
Number of subjects: 1131
Study 22318383 — intervention group
Group type: COMPARATOR
Intervention: Matching vehicle control
Number of subjects: 1131
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy by endoscopists with low activity volume (< 85 sigmoidoscopies/year)
Number of subjects: 13764
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists with a lower rate of incomplete sigmoidoscopy (< 9 %)
Number of subjects: 13764
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists with a higher rate of incomplete sigmoidoscopy (> 12 %)
Number of subjects: 13764
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 13764
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of one first-degree relative with colorectal cancer (CRC)
Number of subjects: 13764
Study 20414864 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of recent-onset rectal bleeding
Number of subjects: 13764
Study 18583869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 40
Study 18583869 — intervention group
Group type: COMPARATOR
Intervention: Soft snare occlusion
Number of subjects: 40
Study 16055161 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐linked proanthocyanidins from cranberry juice cocktail at 60 microg/ml
Number of subjects: 0
Study 16055161 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐type proanthocyanidins from grape at 1200 microg/ml
Number of subjects: 0
Study 16055161 — intervention group
Group type: EXPERIMENTAL
Intervention: Other B‐type proanthocyanidins from commercial products
Number of subjects: 0
Study 16055161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice cocktail consumption
Number of subjects: 0
Study 16055161 — intervention group
Group type: COMPARATOR
Intervention: Non-cranberry food products consumption
Number of subjects: 0
Study 11736673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg kg(‐1) with fentanyl 100 microg)
Number of subjects: 30
Study 11736673 — intervention group
Group type: COMPARATOR
Intervention: Halothane (with fentanyl 100 microg)
Number of subjects: 30
Study 11736673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 11736673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (Propofol)
Number of subjects: 30
Study 9225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.52 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Number of subjects: 8
Study 9225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.69 g/kg during 2 hours and 0.3 g/kg during 3 hours)
Number of subjects: 8
Study 9225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (higher dose)
Number of subjects: 8
Study 9225827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (both studies)
Number of subjects: 8
Study 9225827 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 8352178 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 108
Study 8352178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 3626897 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Choice Test (MCQ)
Number of subjects: 36
Study 3626897 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed Free Response
Number of subjects: 36
Study 3626897 — intervention group
Group type: COMPARATOR
Intervention: Random Context
Number of subjects: 36
Study 2585237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered immune globulin (IVIG)
Number of subjects: 200
Study 2585237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 2585237 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (non-randomized group)
Number of subjects: 200
Study 31112737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 54
Study 31112737 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 54
Study 27862898 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablet (ODT; 10-100 μg)
Number of subjects: 0
Study 27862898 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum effective dose of desmopressin (25 μg in women, 50 μg in men) with a sodium monitoring plan
Number of subjects: 0
Study 27862898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Current rhinitis
Number of subjects: 218
Study 26365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis severity
Number of subjects: 218
Study 26365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic rhinitis
Number of subjects: 218
Study 26365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis symptom severity
Number of subjects: 218
Study 26365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved asthma control
Number of subjects: 218
Study 24084400 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (group-based, peer-delivered physical activity intervention)
Number of subjects: 34
Study 21654683 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP Intervention
Number of subjects: 867
Study 21654683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 867
Study 21654683 — intervention group
Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 867
Study 20023357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (Hylan G‐F 20)
Number of subjects: 63
Study 20023357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 63
Study 16911176 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills training (LST) program
Number of subjects: 170
Study 16911176 — intervention group
Group type: COMPARATOR
Intervention: Control group (tobacco and drug education curriculum)
Number of subjects: 170
Study 16209203 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (antibiotic, indomethacin, alpha1 receptor blocker and Chinese traditional medicine)
Number of subjects: 346
Study 16209203 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine medication plus psychologic treatment
Number of subjects: 346
Study 11318296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL
Number of subjects: 104
Study 11318296 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 104
Study 11318296 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer and Tonopen XL
Number of subjects: 104
Study 9644786 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 20 mg/40 ml
Number of subjects: 10
Study 9644786 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 50 mg/100 ml
Number of subjects: 10
Study 7942792 — intervention group
Group type: EXPERIMENTAL
Intervention: B-CLL cells
Number of subjects: 16
Study 7942792 — intervention group
Group type: COMPARATOR
Intervention: Normal lymphocytes
Number of subjects: 16
Study 3366160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (5 mg i.v.)
Number of subjects: 30
Study 3366160 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 31487739 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (50 mg, i.v.)
Number of subjects: 68
Study 31487739 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (0.1 mL/kg, i.v.)
Number of subjects: 68
Study 30640362 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg once weekly for 48 weeks
Number of subjects: 60
Study 30640362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28667201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) in conjunction with treatment as usual (mostly pharmacotherapy and clinical monitoring)
Number of subjects: 58
Study 28667201 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 58
Study 25451583 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 16
Study 25451583 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 16
Study 25451583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary control
Number of subjects: 16
Study 22819205 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus SSRI
Number of subjects: 220
Study 22819205 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 220
Study 21946897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS7 high risk (n=440)
Number of subjects: 938
Study 21946897 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS7 medium risk (n=310)
Number of subjects: 938